News
Public · Published
Blackstone, Boston Scientific Sign $455 Million Deal to Co-Fund Heart Pump
Blackstone Life Sciences signed a $455 million deal with Boston Scientific to co-fund development of Vitalyst, a minimally invasive heart pump. The device is designed to support heart pumping without open-heart surgery and treat cardiogenic shock, when the heart cannot pump enough blood. The companies have not previously collaborated to fund a Boston Scientific product.
Published:
Updated:
What happened
Blackstone Life Sciences signed a $455 million deal with Boston Scientific to co-fund development of Vitalyst, a minimally invasive heart pump. The device is designed to support heart pumping without open-heart surgery and treat cardiogenic shock, when the heart cannot pump enough blood. The companies have not previously collaborated to fund a Boston Scientific product.
Confirmed
Global impact / market context
The deal shares the cost of developing Vitalyst between the two companies. Boston Scientific keeps more cash available for other projects while Blackstone gains a stake in a heart pump it says could improve safety and effectiveness. Success could add a new product to Boston Scientific's heart device lineup.
Analyst inference
Boston Scientific is betting that outside funding can speed an experimental heart pump toward market. For Blackstone, the deal puts money into a medical device rather than a conventional investment. The companies still need to show Vitalyst works safely and effectively before it can reach patients and earn revenue.
Analyst inference
What to watch
- Watch for updates on the Vitalyst heart pump's development and any clinical testing, since the device is still being developed to treat cardiogenic shock. Confirmed
- Watch whether the $455 million covers the full development cost or whether Boston Scientific and Blackstone must commit additional money for testing and regulatory steps. Analyst inference
- Watch for signs the two companies expand their funding partnership to other Boston Scientific products, since this is their first such collaboration. Proposed
Evidence
- Original source link unavailable